Our Team
We are a mission-aligned team with expertise across human biology, immunology, chemistry, computational biology, data science, machine learning, drug development, clinical, and commercial leadership.
Our Purpose
We are drawn together by our shared purpose and relentless hunger to improve health outcomes for as many people as possible while reducing the growing chronic disease burden. Our approach to innovation is uniquely human-centered — unlocking connections between diverse untapped chemistry and biological pathways driving disease to create solutions preferred by patients and clinicians that are designed to transform the treatment of disease.
We have brought together an inclusive, interdependently ambitious, and high-performing team with the courage to learn, iterate and make leaps together. We approach our work with humility, acknowledging and embracing the complexity of the disciplines we need to bring together and the many unknowns in human biology. Given the scalability of our platform, we seek to be best in class collaborators with our industry partners to help rapidly advance as many therapies as possible to improve patient's lives.
Board of Directors
-
Noubar Afeyan, Ph.D.
Co-Founder and Board DirectorFounder & CEO, Flagship Pioneering -
Margo Georgiadis
Co-Founder and CEO; Board Director -
Ignacio Martinez
Co-Founder and Board DirectorGeneral Partner, Flagship Pioneering -
Lord Ara Darzi, M.D.
Chair of the BoardDirector of the Institute of Global Health Innovation at Imperial College London and Chair of Imperial College Health Partners; Honorary Consultant Surgeon at Imperial College Hospital NHS Trust -
Phyllis Yale
Board DirectorChair of the Board, Blue Cross Blue Shield of Massachusetts and Kindred Healthcare, Inc.; Board Member, Bristol-Myers Squibb; Former Senior Partner and Leader of Healthcare Practice, Bain & Company -
Andreas Fibig
Board DirectorFormer Chairman and CEO, International Flavors & Fragrances; Former Chairman and President, Bayer Healthcare Pharmaceuticals -
Michael Severino, M.D.
Board DirectorCEO, Tessera Therapeutics; Former Vice Chairman and President, Abbvie; Former SVP and CMO, Amgen -
David Khougazian
Board DirectorGrowth Partner, Flagship Pioneering -
Larry Hamann
Board DirectorCo-founder and CEO of Interdict Bio; Former Global Head, Drug Discovery Sciences, Takeda Pharmaceuticals -
Pietro Antonio Tataranni, M.D.
Board ObserverChief Medical Officer, PepsiCo; Former SVP, Head of Medical Affairs, Diabetes and Cardiovascular, Sanofi
OUR SCIENTIFIC ADVISORY BOARD
-
Connor Coley, Ph.D.
Assistant Professor of Chemical Engineering & Electrical Engineering and Computer Science, MIT -
Jim Collins, Ph.D.
Termeer Professor of Medical Engineering & Science, MIT; Core Founding Faculty Member, Wyss Institute, Harvard; Institute Member, Broad Institute of MIT and Harvard -
Keith James, Ph.D.
Former President, Ferring Research Institute, and Senior Vice-President and Head of Drug Discovery at Insitro and Pfizer -
Iain McInnes, Ph.D., M.B.Ch.B
Vice Principal and Head of College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine, Versus Arthritis Professor of Rheumatology, University of Glasgow -
Luke O'Neill, Ph.D.
Professor and Chair of Biochemistry and Immunology, Trinity College -
Paul Ridker, M.D.
Eugene Braunwald Professor of Medicine, Harvard University and Brigham and Women's Hospital; Director of the Center for Cardiovascular Disease Prevention -
Peter Sorger, Ph.D.
Otto Krayer Professor of Systems Pharmacology, Head of the Harvard Program in Therapeutic Sciences (HiTS), Harvard Medical School; Cofounder, Merrimack Pharmaceuticals
Join Us
Contact Us
-
Partnerships
We welcome the opportunity to partner with experts across areas who share our passion for creating Anthromolecule™ medicines and want to collaborate to accelerate the development of safe, efficacious and accessible therapies across diseases.
partnerships@montai.com -
Press
For media inquiries or the latest on research, thought leadership, company news, and events contact:
press@montai.com